Baltimore, MD, February 11, 2015 – NanoAxis and Avanti Therapeutics will jointly launch NanoAxis Neurosciences to be located in the state of Maryland. The partnership will incorporate Avanti programmable therapeutic platform to advance drug and gene therapy development and discovery for central nervous system diseases currently in NanoAxis pipeline. According to current market reports, the blood brain barrier market will reach half-billion by 2019, with a compounded average growth rate of 65%. NanoAxis Neurosciences poises to be an early entrant in an expanding market. The jointly developed technology will allow selective gene and drug targeting in the brain. NanoAxis Neurosciences will develop its Alzheimer’s program as its lead candidate. The Alzheimer’s drug market peaked last year at $10.2 billion.
Other viable preclinical programs in the NanoAxis neuroscience pipeline will target Epilepsy, Depression, and Chronic Pain. The programmable therapeutic model will advance the personalized medical care evolution that is taking place in healthcare. The combination platform will allow for patient treatment tailored to their specific needs by a combination of sophisticated engineering principles that will start at the nano-level. The therapy will not only be unique in its biological targets for each disease process, but by being patient-oriented, it will allow increased compliance, decreased side effects, and rapid recovery and treatment. “Our approach with Avanti will be radically different than other companies developing Alzheimer’s gene and drug therapy candidates out there. Alzheimer’s disease is a growing problem, and the number of affected people will continue to see a rapid rise as better diagnostic tools are going to be developed. With generic alternatives on the way, our technology has a lot of scientific and commercial potential and promise. Avanti has shown their platform works in the cancer area and are beginning clinical trials, we hope to develop a parallel approach in the neuroscience front."
Dr. Krishnan Chakravarthy, MD, PhD – Chairman and CEO of NanoAxis, Affiliated Faculty at the Johns Hopkins Institute of Nano biotechnology, resident physician Department of Anesthesiology and Critical Care Medicine. “After successfully implementing Aayush Biosphere for the development of clinical outcome focused products for the treatment of cancer (Chikujee Therapeutics), development of precision medicine products for central nervous systems is the next step in making the platform a truly unified therapeutic development platform.” says Dr. Arkesh Mehta, Ph. D - Chairman of Avanti Group of Companies.
About NanoAxis
NanoAxis, LLC (www.nanoaxisllc.com) is a leading nanomedicine and technology company based in Buffalo, NY, which utilizes nanomaterial for the development of new Nano medicine applications across both diagnostic and therapeutic domains. We work with various academic and industrial customers by offering them practical and cost-effective solutions to their specific problems as relates to the use of nanomaterials for various life science applications. Areas of biological interest and current product platforms include the creation of new medical devices, gene therapy applications, and targeted drug delivery by employing unique nanoparticle based technologies.
About Avanti Therapeutics
Avanti Therapeutics is a leading innovative technology - based biopharmaceutical company based in Germantown, Maryland, that develops and commercializes programmable logic therapeutics for the treatment of serious medical conditions. Avanti Therapeutics has a diverse product portfolio with product candidates in development in areas of high unmet medical need, including hypercholesterolemia, oncology, CNS diseases, regenerative medicine and infectious diseases. Avanti Therapeutics has developed Aayush Biosphere - a unified therapeutic development platform – for clinical outcome based development of next generation of Therapeutic drugs. For additional information about the company, please visit www.avantitherapeutics.com.
Help employers find you! Check out all the jobs and post your resume.
Other viable preclinical programs in the NanoAxis neuroscience pipeline will target Epilepsy, Depression, and Chronic Pain. The programmable therapeutic model will advance the personalized medical care evolution that is taking place in healthcare. The combination platform will allow for patient treatment tailored to their specific needs by a combination of sophisticated engineering principles that will start at the nano-level. The therapy will not only be unique in its biological targets for each disease process, but by being patient-oriented, it will allow increased compliance, decreased side effects, and rapid recovery and treatment. “Our approach with Avanti will be radically different than other companies developing Alzheimer’s gene and drug therapy candidates out there. Alzheimer’s disease is a growing problem, and the number of affected people will continue to see a rapid rise as better diagnostic tools are going to be developed. With generic alternatives on the way, our technology has a lot of scientific and commercial potential and promise. Avanti has shown their platform works in the cancer area and are beginning clinical trials, we hope to develop a parallel approach in the neuroscience front."
Dr. Krishnan Chakravarthy, MD, PhD – Chairman and CEO of NanoAxis, Affiliated Faculty at the Johns Hopkins Institute of Nano biotechnology, resident physician Department of Anesthesiology and Critical Care Medicine. “After successfully implementing Aayush Biosphere for the development of clinical outcome focused products for the treatment of cancer (Chikujee Therapeutics), development of precision medicine products for central nervous systems is the next step in making the platform a truly unified therapeutic development platform.” says Dr. Arkesh Mehta, Ph. D - Chairman of Avanti Group of Companies.
About NanoAxis
NanoAxis, LLC (www.nanoaxisllc.com) is a leading nanomedicine and technology company based in Buffalo, NY, which utilizes nanomaterial for the development of new Nano medicine applications across both diagnostic and therapeutic domains. We work with various academic and industrial customers by offering them practical and cost-effective solutions to their specific problems as relates to the use of nanomaterials for various life science applications. Areas of biological interest and current product platforms include the creation of new medical devices, gene therapy applications, and targeted drug delivery by employing unique nanoparticle based technologies.
About Avanti Therapeutics
Avanti Therapeutics is a leading innovative technology - based biopharmaceutical company based in Germantown, Maryland, that develops and commercializes programmable logic therapeutics for the treatment of serious medical conditions. Avanti Therapeutics has a diverse product portfolio with product candidates in development in areas of high unmet medical need, including hypercholesterolemia, oncology, CNS diseases, regenerative medicine and infectious diseases. Avanti Therapeutics has developed Aayush Biosphere - a unified therapeutic development platform – for clinical outcome based development of next generation of Therapeutic drugs. For additional information about the company, please visit www.avantitherapeutics.com.
Help employers find you! Check out all the jobs and post your resume.
